Advanced Therapies Europe 2020

29TH - 30TH SEPTEMBER 2020



Peter Olagunju

Peter Olagunju

Vice President Patient Operations, bluebird bio

Peter leads the Patient Operations function which is the primary point of contact within the CMC function at bluebird bio for Centers of Excellence (COE) interfaces including the collection of patient cells, manufacture of drug product, and operational execution of patient treatments. Creating an optimized point of care experience for patients, providers, and stakeholders related to the treatment process. Peter is also the program leader for LentiGlobin, which is being evaluated for patients with Transfusion Dependent Thalassemia (TDT). As the Program lead, he isesponsible for the Program team which is comprised of cross functional representatives spanning research, development, and commercial.

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd